JP2024509701A5 - - Google Patents
Info
- Publication number
- JP2024509701A5 JP2024509701A5 JP2023547272A JP2023547272A JP2024509701A5 JP 2024509701 A5 JP2024509701 A5 JP 2024509701A5 JP 2023547272 A JP2023547272 A JP 2023547272A JP 2023547272 A JP2023547272 A JP 2023547272A JP 2024509701 A5 JP2024509701 A5 JP 2024509701A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cdr
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163147483P | 2021-02-09 | 2021-02-09 | |
| US63/147,483 | 2021-02-09 | ||
| PCT/EP2022/053095 WO2022171656A1 (en) | 2021-02-09 | 2022-02-09 | Anti-s100a4 humanized antibodies, uses and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024509701A JP2024509701A (ja) | 2024-03-05 |
| JP2024509701A5 true JP2024509701A5 (enExample) | 2025-08-20 |
| JP7824969B2 JP7824969B2 (ja) | 2026-03-05 |
Family
ID=80446273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547272A Active JP7824969B2 (ja) | 2021-02-09 | 2022-02-09 | 抗ｓ１００ａ４ヒト化抗体、使用及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240043521A1 (enExample) |
| EP (1) | EP4291579A1 (enExample) |
| JP (1) | JP7824969B2 (enExample) |
| CN (1) | CN117480182A (enExample) |
| AU (1) | AU2022219476A1 (enExample) |
| CA (1) | CA3207703A1 (enExample) |
| IL (1) | IL304971A (enExample) |
| WO (1) | WO2022171656A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022003042A1 (en) * | 2020-06-30 | 2022-01-06 | Arxx Therapeutics As | Anti-s100a4 antibodies for the treatment of systemic sclerosis |
| US20250011405A1 (en) * | 2021-11-19 | 2025-01-09 | Lykera Biomed, S.A. | Treatment and diagnosis of diseases associated to pathogenic fibrosis |
| CN115819577A (zh) * | 2022-10-08 | 2023-03-21 | 河南赛诺特生物技术有限公司 | 一种抗s100a单克隆抗体及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103201290B (zh) * | 2010-06-14 | 2016-09-28 | 莱克拉生物医学股份公司 | S100a4抗体及其治疗用途 |
| GB201219487D0 (en) * | 2012-10-30 | 2012-12-12 | Cancer Rec Tech Ltd | Anti-S100A4 antibody molecules and their uses |
| IL315266A (en) * | 2016-06-14 | 2024-10-01 | Merck Sharp ַ& Dohme Llc | Anti-coagulation factor xi antibodies |
| CN107375923A (zh) * | 2017-07-06 | 2017-11-24 | 北京多赢时代转化医学研究院 | 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用 |
-
2022
- 2022-02-09 CA CA3207703A patent/CA3207703A1/en active Pending
- 2022-02-09 IL IL304971A patent/IL304971A/en unknown
- 2022-02-09 JP JP2023547272A patent/JP7824969B2/ja active Active
- 2022-02-09 EP EP22705764.3A patent/EP4291579A1/en active Pending
- 2022-02-09 US US18/264,483 patent/US20240043521A1/en not_active Abandoned
- 2022-02-09 WO PCT/EP2022/053095 patent/WO2022171656A1/en not_active Ceased
- 2022-02-09 AU AU2022219476A patent/AU2022219476A1/en active Pending
- 2022-02-09 CN CN202280013560.3A patent/CN117480182A/zh active Pending
-
2024
- 2024-11-27 US US18/962,263 patent/US12304949B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022079549A5 (enExample) | ||
| US20240287187A1 (en) | Bispecific antibody | |
| US8877194B2 (en) | TNF-α binding proteins | |
| JP2021524267A5 (enExample) | ||
| JP2021524268A5 (enExample) | ||
| JP2024509701A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| JP2018533371A5 (enExample) | ||
| JP2018526981A5 (enExample) | ||
| KR20110110349A (ko) | Ｉｌ-1 결합 단백질 | |
| RU2012118636A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2024541680A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| JP2023511963A5 (enExample) | ||
| JP2023530663A5 (enExample) | ||
| JP2026004299A5 (enExample) | ||
| JP2022516071A5 (enExample) | ||
| JP2023548529A5 (enExample) | ||
| JP2023508674A5 (enExample) | ||
| JP2022527084A5 (enExample) | ||
| AU2020322765A1 (en) | Bispecific antibody | |
| JP2025500805A5 (enExample) | ||
| JP2024523514A5 (enExample) | ||
| CA2538725A1 (en) | Nogo-a binding molecules and pharmaceutical use thereof | |
| US20260028396A1 (en) | Anti-myostatin antibodies and methods |